抄録
Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.
| 元の言語 | English |
|---|---|
| ページ（範囲） | 455-462 |
| ページ数 | 8 |
| ジャーナル | Journal of Neuro-Oncology |
| 巻 | 137 |
| 発行部数 | 3 |
| DOI | |
| 出版物ステータス | Published - 01-05-2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Neurology
- Clinical Neurology
- Cancer Research
これを引用
}
Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis. / Kimura, Akio; Takemura, Masao; Serrero, Ginette; Yoshikura, Nobuaki; Hayashi, Yuichi; Saito, Kuniaki; Inuzuka, Takashi.
：: Journal of Neuro-Oncology, 巻 137, 番号 3, 01.05.2018, p. 455-462.研究成果: Article
TY - JOUR
T1 - Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis
AU - Kimura, Akio
AU - Takemura, Masao
AU - Serrero, Ginette
AU - Yoshikura, Nobuaki
AU - Hayashi, Yuichi
AU - Saito, Kuniaki
AU - Inuzuka, Takashi
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.
AB - Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.
UR - http://www.scopus.com/inward/record.url?scp=85042767843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042767843&partnerID=8YFLogxK
U2 - 10.1007/s11060-017-2742-z
DO - 10.1007/s11060-017-2742-z
M3 - Article
C2 - 29340960
AN - SCOPUS:85042767843
VL - 137
SP - 455
EP - 462
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
IS - 3
ER -